With its groundbreaking tauopathy therapeutics program, Treventis has demonstrated how CCM can enable protein misfolding drug design. The company is expanding its CCM platform into other indications including in oncology and other neurodegenerative disorders.

Tau Oligomer Inhibitors (3R/4R) p53 Oligomer Inhibitor Broad Spectrum TDP Oligomer Inhibitor Alzheimers Cancer Amyotrophic Lateral Sclerosis ALS